# Pedicled myofascial temporalis flap for closure of large maxillary defects after medication-related osteonecrosis of the jaws. A case series

**Authors:** Sanne Werner Moeller Andersen, Liezl Dawson, Iben Poulsen, Simon Storgaard Jensen, Thomas Kofod

PMC · DOI: 10.1007/s10006-026-01532-w · Oral and Maxillofacial Surgery · 2026-02-26

## TL;DR

This study shows that a specific surgical flap can successfully repair large maxillary defects caused by a severe jaw condition.

## Contribution

Demonstrates the effectiveness of the pedicled myofascial temporalis flap for maxillary defect closure in stage 3 MRONJ.

## Key findings

- Seven patients with extensive maxillary defects achieved complete mucosal closure using PMTF.
- All patients experienced uneventful healing at the recipient site and reduced postoperative pain.
- One late donor-site complication occurred, but no flap-related failures were observed.

## Abstract

Medication-related osteonecrosis of the jaws (MRONJ) located in the maxilla may lead to challenging oro-antral and oro-nasal defects too extensive to be predictably closed with local soft tissue flaps. The use of a pedicled myofascial temporalis flap (PMTF) is, however, well-established for closing large maxillary defects following ablative craniomaxillofacial surgery.

The purpose of the present study was to evaluate the use of PMTF for maxillary defect closure in patients with stage 3 MRONJ.

A retrospective cohort study was conducted based on data from the Copenhagen ONJ cohort from 1 January 2005 to 31 December 2024. The inclusion criteria were consecutive patients with extensive maxillary defects after surgical treatment of MRONJ and reconstruction with PMTF.

Seven patients met the inclusion criteria (three with cancer, two with osteoporosis, and two with both conditions). All defects were successfully closed using the PMTF. Healing was uneventful in all patients at the recipient site, with complete mucosal closure achieved. Postoperative pain was reduced in all cases. One patient developed a late donor-site complication requiring removal of the temporal implant; no flap-related failures occurred.

The removal of necrotic bone combined with radical sinusotomy and closure of the defect with PMTF appears to be a feasible approach for managing extensive maxillary MRONJ lesions, with favourable outcomes observed in this limited cohort.

## Linked entities

- **Diseases:** osteoporosis (MONDO:0005298)

## Full-text entities

- **Genes:** BTF3P11 (basic transcription factor 3 pseudogene 11) [NCBI Gene 690] {aka BRF3L1, BTF3L1, HUMBTFB, OCIF, OPG, TNFRSF11B}
- **Diseases:** alopecia (MESH:D000505), MRONJ lesion (MESH:D009059), orbital cellulitis (MESH:D054517), Pain (MESH:D010146), dehiscence (MESH:D013529), necrotic skin (MESH:D012871), sinusitis (MESH:D012852), gout (MESH:D006073), abscess (MESH:D000038), acute and chronic inflammation (MESH:D007249), MRONJ defects (MESH:D000013), necrotic cutis (MESH:D000092182), chronic renal insufficiency (MESH:D051436), trismus (MESH:D014313), multiple myeloma (MESH:D009101), ischemic (MESH:D002545), necrotic bone (MESH:D010020), cancer (MESH:D009369), Postoperative pain (MESH:D010149), hypercholesterolemia (MESH:D006937), septal (MESH:D006343), depression (MESH:D003866), breast cancer (MESH:D001943), paralysis of the frontal branch of the facial nerve (MESH:D005158), PMTF (MESH:D000070600), oncologic (MESH:D000072716), fistulae (MESH:D005402), Necrotic (MESH:D009336), hypertension (MESH:D006973), death (MESH:D003643), facial nerve dysfunction (MESH:D005155), impaired masticatory function (MESH:C563600), impaired speech and swallowing (MESH:D003680), bone loss (MESH:D001847), osteolysis (MESH:D010014), maxillary defect (MESH:D008439), osteonecrosis of the jaws (MESH:D059266), osteoporosis (MESH:D010024), AR (MESH:D016609), infection (MESH:D007239), oro-nasal defects (MESH:D009668)
- **Chemicals:** PMMA (MESH:D019904), polyethylene (MESH:D020959), P (MESH:D010758), zinc (MESH:D015032), PEEK (MESH:C063834), uric acid (MESH:D014527), amoxicillin/clavulanic acid (MESH:D019980), Alendronate (MESH:D019386), steroid (MESH:D013256), Denosumab (MESH:D000069448), cefuroxime (MESH:D002444), Letrozole (MESH:D000077289), Marcaine Adrenaline (-), methylrosaniline (MESH:D005840), dexamethasone (MESH:D003907), Lenalidomide (MESH:D000077269), Synalar (MESH:D005446), titanium (MESH:D014025), PEKK (MESH:C000624694), Mersilene (MESH:C025539)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945897/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945897/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945897/full.md

---
Source: https://tomesphere.com/paper/PMC12945897